Evidence mapPaperPMID 41965878Full record

ArticleNature communications2026

CBP/p300 is critical for the expansion and maintenance of functional pancreatic α cell mass.

Shushu Wang, Tianjiao Li, Chunxiang Sheng, Jialin Tan, Yuling Yang, Xiaoqin Ma, Yun Liu, Rui Wei, Feiye Zhou, Libin Zhou and 1 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Shushu Wang *Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Tianjiao Li *Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Chunxiang Sheng *Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jialin TanDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yuling YangDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xiaoqin MaDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yun LiuDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Rui WeiDepartment of Endocrinology and Metabolism, State Key Laboratory of Female Fertility Promotion, Peking University Third Hospital, Beijing, China.ORCID http://orcid.org/0000-0002-8838-703X
Feiye ZhouDepartment of Endocrinology and Metabolism, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. zhoufeiye605@163.com.
Libin ZhouDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. libinzhou99@hotmail.com.ORCID http://orcid.org/0000-0002-1297-0165
Xiao WangDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. wangxiao1976@hotmail.com.ORCID http://orcid.org/0000-0002-5837-2996

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82270860National Natural Science Foundation of China (National Science Foundation of China) 82300896National Natural Science Foundation of China (National Science Foundation of China) 82370798
6 · The paper itself

Abstract

Pancreatic α cell senses amino acid availability to adjust secretion function and proliferation, yet the underlying molecular mechanisms remain unclear. Here, α cell-specific deletion of CBP/p300 in mice leads to hypoglucagonemia and hyperaminoacidemia, along with decreased functional pancreatic α cell mass due to impaired cell proliferation, dedifferentiation, and cell loss. The knockout of CBP/p300 blocks glucagon receptor antibody-stimulated α cell proliferation and mTORC1 signaling in mice. In CBP/p300-deficient α cells, single-cell RNA sequencing reveals upregulated autophagy-related genes and downregulated α cell identity genes and amino acid transporters, including Slc7a2. Slc7a2 is involved in regulating α cell identity gene expression through lysine-facilitated H3K27 acetylation. In addition, Slc7a2 downregulation compromises arginine-stimulated mTORC1 signaling, thereby suppressing α cell proliferation and triggering autophagy. Collectively, our findings uncover CBP/p300 as central regulators of functional α cell mass partially by orchestrating Slc7a2-mediated amino acid sensing.

Indexed as

E1A-Associated p300 ProteinGlucagon-Secreting CellsAmino AcidsAnimalsAutophagyCell ProliferationMaleMechanistic Target of Rapamycin Complex 1MiceMice, KnockoutSignal TransductionAmino AcidsE1A-Associated p300 ProteinEp300 protein, mouseMechanistic Target of Rapamycin Complex 1

Identifiers

PMID41965878
PMCPMC13247099

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.